Pharmacy Benefits Management
Dear Manufacturer Letter

Public Law 102-585 (38 U.S.C. 8126)
Section 603

The Veteran’s Healthcare Act of 1992 (“the Act”)

# TABLE OF CONTENTS

I. Introduction ........................................................................................................... 3

II. Background ........................................................................................................... 3  
   a. Purpose ............................................................................................................ 3  
   b. Expectations .................................................................................................. 3  
   c. System requirements ...................................................................................... 3  

III. Public Law Timetable (Overview) .................................................................. 3  

IV. Detailed Timeline ............................................................................................... 4  

V. Excel Data Dictionary ....................................................................................... 5-6  

VI. General Guidance ............................................................................................. 7-8  

VII. Attachments .................................................................................................... 9-14  
   A. Methodology Changes .................................................................................. 9  
   B. Workbook Verification Disputes ................................................................. 10-11  
   C. Compliance reminders ............................................................................... 12  
   D. FCP Disputes .............................................................................................. 13  
   E. Self-Disclosure ............................................................................................. 14  
   F. Appeal to the Nominal Increase Board ...................................................... 15
I. INTRODUCTION

The Office of Pharmacy Benefits Management Services (PBM) is responsible for maintaining calculated federal ceiling prices (FCPs) for covered drugs through the Public Law annual reporting process. All companies of covered drugs are obligated to comply with the reporting requirements under Public Law 102-585, Section 603.

II. BACKGROUND


a. PURPOSE

The purpose of this Dear Manufacturer Letter (DML) is to provide companies with guidance on complying with the 2021 annual non-FAMP reporting requirements (for 2022 FCPs) under Public Law 102-585, Section 603. Please retain a copy of this DML as it contains guidance in Parts VI and VII of this letter on various Public Law issues that frequently occur.

b. EXPECTATIONS

PBM will provide your company’s point of contact with an Excel workbook that is pre-populated with data. It is the company’s responsibility to verify the accuracy of the data in this workbook. Follow the guidance in this letter to report any disputes to the VA. If there are no disputes to the pre-populated data in the Excel workbook, you are advised to populate the workbook with data values as explained in this letter and return electronically to VA before the November 15, 2021 deadline. The excel data dictionary and Attachment C provide a list of compliance reminders to assist with your annual filing.

c. SYSTEM REQUIREMENTS

To comply with the annual reporting requirements, electronic mail (e-mail) and a computer loaded with Microsoft Excel (.xls) program is required.

III. 2021 Year PUBLIC LAW TIMETABLE (OVERVIEW)

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>OCT 13</td>
<td>CPI-U Published</td>
</tr>
<tr>
<td>OCT 18</td>
<td>Workbook Verification</td>
</tr>
<tr>
<td>OCT 29</td>
<td>Deadline</td>
</tr>
<tr>
<td>NLT   NOV 4</td>
<td>NAC Letter</td>
</tr>
<tr>
<td>NOV 15</td>
<td>Deadline</td>
</tr>
<tr>
<td>NOV 16</td>
<td>FCP Calculations</td>
</tr>
<tr>
<td>DEC 3</td>
<td>Deadline</td>
</tr>
</tbody>
</table>

PBM calculates the consumer price index-urban (CPI-U%) value and disseminates company’s Excel workbook containing covered drugs subject to annual calculations.

Company reviews VA’s workbook for discrepancies, which may include omissions, FSS price disputes, 3Q disputes or any other discrepancies that may exist and notifies VA.

Last day for companies to submit methodology change requests & related 3Q OLD restatements under (proposed) new methodology; This is also the last day companies may report any disputes identified in the company workbook (FSS Disputes, omissions and 3Q disputes unrelated to methodology change).

Annual filing due; companies that were unable to notify the VA of identified disputes should do so when they file their annual report to PBM on November 15.

PBM will start/continue to process the annual reports; NOTE: pending disputes will be resolved prior to FCP calculations.

Last day to submit request for modification (RFM) to NAC for guaranteed Jan 1 upload price.
IV. DETAILED TIMELINE

By October 15, 2021

Companies’ designated non-FAMP representative will receive an e-mail from AMMHIN.PL102585@va.gov on behalf of the Public Law Manager. This e-mail will contain attachments of a current copy of PBM’s DML and an Excel workbook (.xls) of covered items subject to annual calculations. This Excel workbook (.xls), which is a locked version and contains select prepopulated cells, will be used by companies to complete the 2021 annual non-FAMP reporting requirements (for 2022 FCPs). Pages 5-6 of this DML provide the data dictionary of this Excel workbook.

October 18, 2021

Workbook Verification: **Companies must review the Excel workbook upon receipt for any disputes and discrepancies.**

Companies are advised to notify the VA of any disputes in the Excel workbook via e-mail as outlined in this guidance letter. Please note: not all covered drugs are eligible for annual non-FAMP calculations; the workbook will only contain covered items that are subject to the annual non-FAMP calculation reporting. Companies must report all covered drug items that had/should have had a Permanent FCP in place on September 30, 2021, for the purpose of determining FCPs for Calendar Year 2022. **NOTE:** the FSS price that is in effect on September 30, 2021, as reflected in this workbook, which is used for Public Law calculations, does not include the Industrial Funding Fee (IFF) or the Federal Excise Tax (FET) for vaccines. Disputes and discrepancies should follow the dispute process outlined in Attachment B.

By October 29, 2021

- Deadline for companies to report any Workbook Verification disputes via e-mail to AMMHIN.PL102585@va.gov, as instructed in Attachment A. The VA will review the requests and communicate a resolution to the company. At this point, and to reduce e-mail traffic, a corrected workbook with revised data values will not be re-issued. The corrected values will be used in calculations and will reflect in the final FCP report to the company. To ensure accuracy in calculations, please provide a copy of the approved methodology communication when your company files the annual report. Companies that submit 3Q disputes due to methodology change requests after October 29 can expect increased delays in receiving their 2022 FCP calculations.

- Deadline for companies to report any Workbook Verification disputes via e-mail to AMMHIN.PL102585@va.gov, as instructed in Attachment B. Disputes can include any combinations of: a covered drug(s) FSS price that was in effect or awarded on September 30, 2021; any dispute(s) of the calculated non-FAMP for the 3Q non-FAMP Old value (07/01/2020 through 09/30/2020); the listing of drug items subject to the annual calculations, such as omitted items; or other disputes as to the accuracy of the contents of the Excel workbook (.xls) that was received. The VA will validate the disputes and communicate a resolution to the company. At this point, and to reduce e-mail traffic, a corrected workbook with revised data values will not be re-issued. The corrected values will be used in calculations and will reflect in the final FCP report to the company.

To ensure accuracy, please provide a copy of VA’s approved resolution when your company files the annual report. Companies that submit identified disputes after November 1 can expect increased delays in receiving their 2022 FCP calculations.

By November 15, 2021

- **Companies must report the annual non-FAMP (10/01/2020 through 09/30/2021) and 3Q non-FAMP New (07/01/2021 through 09/30/2021) calculations to the VA via e-mail to AMMHIN.PL102585@va.gov using the Excel workbook (.xls) provided by the PBM Public Law Manager.** At this point in time, PBM will only re-issue corrected workbooks for extreme cases. **IMPORTANT:** Your Company must include a copy of VA’s approved resolution for identified disputes when filing the annual report to the VA. It is possible that your company has submitted disputes by the requested deadline to the VA, but the disputes are pending VA resolution. To remain compliant with the November 15 filing deadline, the company must submit their annual filing along with a copy of the original dispute verification e-mail along with current resolution status, if any. Companies that have not verified the contents of their Excel workbooks for disputes or omissions by this time must identify any disputes when they submit their annual report due on November 15, 2021. Calculations will not begin until all disputes have been resolved. Attachment C provides a list of compliance reminders.

By November 16, 2021

The PBM Public Law Manager will start to calculate the covered items’ changes in non-FAMP, additional discounts (if any), and the 2021 FCP (if not already in process). Companies are encouraged to submit their annual reports early, as FCP calculations are completed on a first-in first-out basis. Once the calculations are completed, the Excel workbook (.xls) will be sent by e-mail to the companies’ designated non-FAMP representative. **Companies have two business days to review the 2022 FCPs.** Attachment D instructs how to submit FCP disputes by e-mail.

By December 3, 2021

Companies’ authorized signatories must prepare and sign a new PPA addendum, listing each covered drug and its 2022 FCP. The VA National Acquisition Center (NAC) FSS Service will be issuing additional guidance no later than November 4, 2021 on how to submit a “Request For Modification” (RFM) via e-mail to AMMHIN.PL102585@va.gov to update contract pricing. The properly prepared RFM must be received by December 3, 2021 to guarantee an effective date of January 1, 2022.
<table>
<thead>
<tr>
<th>Field Name</th>
<th>Definition</th>
<th>Edits Allowed</th>
</tr>
</thead>
<tbody>
<tr>
<td>ID</td>
<td>Unique identifier assigned to item in Public Law database</td>
<td>No</td>
</tr>
<tr>
<td>YearID</td>
<td>Calendar year in which the Federal Ceiling Price applies</td>
<td>No</td>
</tr>
<tr>
<td>Prep_date</td>
<td>Date the report is prepared by company. Format = “mm/dd/yyyy”</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>NOTE: Date entered restricted to 10/01/2021 and 01/15/2022</td>
<td></td>
</tr>
<tr>
<td>ndc_1</td>
<td>National Drug Code (NDC); ndc_1 = Labeler code (5 digits)</td>
<td>No</td>
</tr>
<tr>
<td>ndc_2</td>
<td>NDC; ndc_2 = Product code (4 digits)</td>
<td>No</td>
</tr>
<tr>
<td>ndc_3</td>
<td>NDC; ndc_3 = Package code (2 digits)</td>
<td>No</td>
</tr>
<tr>
<td>Unt_pkg</td>
<td>Number of units per package</td>
<td>No</td>
</tr>
<tr>
<td>Date_enter</td>
<td>Date the NDC was reported as first commercially available for sale</td>
<td>No</td>
</tr>
<tr>
<td>Dose_form</td>
<td>Dosage form of the NDC</td>
<td>No</td>
</tr>
<tr>
<td>Strength</td>
<td>NDC strength</td>
<td>No</td>
</tr>
<tr>
<td>FDA_name</td>
<td>NDC name reported by company as listed on FDA registration form</td>
<td>No</td>
</tr>
<tr>
<td>Trade_name</td>
<td>NDC brand name reported by company</td>
<td>No</td>
</tr>
<tr>
<td>Generic_name</td>
<td>NDC generic name</td>
<td>No</td>
</tr>
<tr>
<td>Pct_cpiu</td>
<td>Percent Increase in Consumer Price Index (CPI-U). Calculated by multiplying the difference between the two index numbers by 100 and that product divided by the older of the two CPI-Us. Calculation is rounded to two decimal places; rounding up if 3rd decimal is &gt;=5. Examples: 2.1462 rounds to 2.15; 2.1449 rounds to 2.14</td>
<td>No</td>
</tr>
<tr>
<td>fss</td>
<td>2021 Federal Supply Schedule (FSS) price; the permanent contract price in effect or awarded on September 30, 2021 for single price companies. For dual FSS pricing companies, the 2021 FSS price is September 30, 2021 a awarded permanent contract price charged to other government agencies and authorized FSS users other than the Department of Veterans Affairs (VA), Department of Defense (DoD), US Coast Guard or Public Health Service (PHS). NOTE: The FSS price in this field DOES NOT include the Industrial Funding Fee (IFF) for companies that embed this fee or the Federal Excise Tax (FET) if applicable.</td>
<td>No</td>
</tr>
<tr>
<td>fssmax</td>
<td>2021 Maximum Price; calculated using FSS + Allowable CPI-U% increase.</td>
<td>No</td>
</tr>
<tr>
<td>nfamp</td>
<td>2021 Annual Non-Federal Average Manufacturer price (non-FAMP = “nfamp” in Excel Table for ease of reference) is the weighted average manufacturers’ sales price for the NDC. Calculation is rounded to two decimal places; rounding up if 3rd decimal is &gt;=5. For “false positive” non-FAMPs (negative sales divided by negative units), and no reportable sales, “0.00” should be entered. Activity resulting in negative values should be reported as such. Do not return spreadsheet with blank values.</td>
<td>Yes</td>
</tr>
<tr>
<td>nfamp_old</td>
<td>Non-FAMP for 07/01/2020 thru 09/30/2020. See “nfamp” field above for calculation and reporting requirements.</td>
<td>No</td>
</tr>
<tr>
<td>nfamp_new</td>
<td>Non-FAMP for 07/01/2021 thru 09/30/2021. See “nfamp” field above for general calculation and reporting requirements.</td>
<td>Yes</td>
</tr>
<tr>
<td>nfamp_chg</td>
<td>Difference between “nfamp_new” and the “nfamp_old”. This number can be negative. NOTE: This field is not included in the initial workbook from PBM; included in the final workbook sent to companies with the calculations.</td>
<td>No</td>
</tr>
<tr>
<td>Field Name</td>
<td>Definition</td>
<td>Edits Allowed</td>
</tr>
<tr>
<td>-----------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>add_disc</td>
<td>Difference between “nfamp_chg” and the legislative allowable increase. The allowable increase is the product of the “nfamp_old” and “Percent_cpi”. This number must be $\geq 0.00$. If “nfamp_chg” is negative, then $0.00$ will be populated. NOTE: This field is not included in the initial workbook from PBM; included in the final workbook sent to companies with the calculations.</td>
<td>No</td>
</tr>
<tr>
<td>calcmax</td>
<td>2021 Calculated Ceiling. Calculation based on 38 U.S.C. 8126(d)(2), (a)(2) and (c) is the product of the annual non-FAMP X 0.76, less “add_disc” (additional discount). Calculation is rounded to two decimal places; rounding up if 3rd decimal is $\geq 5$. Examples: 2.1462 rounds to 2.15; 2.1449 rounds to 2.14 NOTE: This field is not included in the initial workbook from PBM; included in the final workbook sent to companies with the calculations.</td>
<td>No</td>
</tr>
<tr>
<td>fcp</td>
<td>2022 Federal Ceiling Price (FCP). Lower of 38 U.S.C. 8126(d)(1) or 38 U.S.C. 8126 (d)(2), (a)(2) &amp; (c). This field is determined by using the lower number of fssmax or calcmax. NOTE: This field is not included in the initial workbook from PBM; included in the final workbook sent to companies with the calculations.</td>
<td>No</td>
</tr>
<tr>
<td>disc_date</td>
<td>This field represents a covered item’s discontinuation date from the manufacturer’s FSS. NOTE: This field is not included in the initial workbook from PBM; included in the final workbook sent to companies with the calculations.</td>
<td>No</td>
</tr>
<tr>
<td>ent_no</td>
<td>FSS contract number assigned by the National Acquisition Center (NAC); current as of 9/30/2021</td>
<td>No</td>
</tr>
<tr>
<td>company_of</td>
<td>Name of the company’s official authorizing and certifying that the data provided in this workbook is accurate</td>
<td>Yes</td>
</tr>
<tr>
<td>dispute_fss</td>
<td>Enter a “Y” to dispute the FSS price. Follow the directions outlined in Attachment C or E, as applicable. If dispute_fss field = Y, then rev_fss field must be populated.</td>
<td>Yes</td>
</tr>
<tr>
<td>dispute_nfamp_old</td>
<td>Enter a “Y” to dispute the 3Q old non-FAMP data if unrelated to methodology change. Please follow the directions in Attachments A, D or E, as applicable. If dispute_nfamp_old = Y, then Rev_nfamp_old field must be populated.</td>
<td>Yes</td>
</tr>
<tr>
<td>rev_fss</td>
<td>Revised FSS price; if company populates the dispute_fss field, then rev_fss should not be blank; Calculation is rounded to two decimal places; rounding up if 3rd decimal is $\geq 5$.</td>
<td>Yes</td>
</tr>
<tr>
<td>Rev_nfamp_old</td>
<td>Revised 3Q old value, if company populates the dispute_nfamp_old field, then rev_nfamp_old should not be blank; Calculation is rounded to two decimal places; rounding up if 3rd decimal is $\geq 5$.</td>
<td>Yes</td>
</tr>
<tr>
<td>non_taa</td>
<td>This field indicates covered item(s) which have been identified as items sourced from a non-U.S., non-designated country under the requirements of the Trade Agreements Act (TAA). They are considered covered drugs as defined by the Veteran’s Health Care Act of 1992, P.L. 102-585, Sect. 603, therefore, your company must continue to report non-FAMP to PBM for any covered drug and maintain a FCP for the drug annually with PBM.</td>
<td>No</td>
</tr>
</tbody>
</table>
VI. GENERAL GUIDANCE

Each covered drug’s mandated FCP for 2022 (the fourth year of FSS multiyear contracts for statutory purposes) will be determined by adopting the lower of two calculation results. These two calculations are described in (1) 38 U.S.C 8126 (d) (1) and (2) 38 U.S.C. 8126 (d) (2), (a) (2) & (c). The same percent change in Consumer Price Index-Urban (CPI-U) will be utilized in performing both calculations. This change in CPI-U is identified as the percent change from September 2020 to September 2021. Using data from the U.S. Bureau of Labor Statistics, the derived percent change was calculated as 5.39%. This will be used as the CPI-U figure for the FCP calculations in November 2021.

The Federal Excise Tax (FET) on vaccines and the one-half of one percent (0.5%) IFF being incorporated into FSS contracts will not be included in calculations of non-FAMP or reporting of FCPs but will be included in the FSS/Big 4 (Department of Veterans Affairs, Department of Defense (DoD), Public Health Service/Indian Health Service, & U.S. Coast Guard) selling price. Please see additional instructions from your respective contracting officer(s).

The Section 8126(d)(1) calculation will begin with the permanent FSS contract price of a covered drug in effect on September 30, 2021. FSS temporary price reduction pricing is not used as the FSS price in effect on September 30, 2021 for the purposes of the dual calculation. The dual calculation is performed for both the single and dual pricing options. For those manufacturers that elected dual FSS pricing, the FSS contract price is the September 30, 2021 price charged to other government agencies and other authorized Schedule users; not the price paid by the Big 4. The appropriate FSS price will then be increased by the above percent change in CPI-U to arrive at the 2022 FSS price cap (FSS Max). This cap applies to all “other users” FSS prices in 2022.

The Section 8126(a)(2) & (c) calculation (Calc Max) will begin by multiplying the 2021 annual non-FAMP by 0.76 and then subtracting any additional discount. The additional discount is the difference between the “old” non-FAMP increased by CPI-U and the “new” non-FAMPs. The lower of the Calc Max calculation and the 2021 FSS price cap (FSS Max) will become the 2022 FCP. If there are “no sales” in a benchmark third quarter of a year that is used to derive the new non-FAMP or old non-FAMP, there can be no additional discount calculation for that particular item. In those cases, negative non-FAMPs should be reported and no additional discount will be calculated; additional discount will be entered as zero (0.00). If a covered drug had no reportable sales in the 2021 annual non-FAMP period, its calculated 2022 FCP will be the lower of: (A) the 2021 FCP increased by an amount equal to the 2021 FCP multiplied by the percent change to the CPI-U (as explained and provided above) OR (B) the FSS price in effect on September 30, 2021 increased by an amount equal to the September 30, 2021 FSS price multiplied by the percent change to the CPI-U.

If they meet the other VA criteria, nominal prices excludable from non-FAMP’s for 2021 calculations must be prices that are less than 10 percent of that particular item’s non-FAMP during the third quarter of 2020(07/01/2020 through 09/30/2020). Where sales to end-users are required for calculation of non-FAMP due to the absence of wholesale sales, you need not include purchases by PHS grantees or disproportionate share hospitals (“covered entities”) if the prices for those transactions were determined by PHS pursuant to Sect. 602 of the Veterans Health Care Act of 1992. Also, in figuring wholesale sales, you need not include the chargebacks required to satisfy end-user purchases by the entities at prices determined by the PHS under Sect. 602, or at prices set in negotiations with the PHS Section 602 pharmaceutical prime vendor (PPV) and any subcontractors. However, sales to these entities at prices not negotiated by the Sect. 602 PPV and lower than Sect. 602 statutorily calculated prices must be included in non-FAMP calculations. Finally, sales of specific inpatient covered drugs to disproportionate share hospitals at Sect. 602 prices may be excluded from non-FAMP if you have properly obtained a “hold harmless letter” from VA (see October 19, 2001 Dear Manufacturer Letter).

Any VA-approved changes in non-FAMP methodology (for example, the 90/10 Rule or smoothing of some of the elements in the non-FAMP calculation require the 3Q non-FAMP Old to be restated using the new methodology to ensure an apples-to-apples comparison for the purposes of the additional discount. Any non-FAMP methodology change that is due to errors, requires a self-disclosure to the VA as instructed in Attachment E.

**VA must require that all wholesale sales (or direct sales where those are the proper beginning point) used for 2021 annual and third quarter 2021 non-FAMP reports (to be filed this November) be reduced by amounts**
VI. GENERAL GUIDANCE (cont’d.)

reflecting certain TRICARE Retail Network usage data posted or transmitted by DoD during the FY 2021 12-month reporting period, because the TRICARE usage constitutes sales to the Federal Government.

Manufacturers will use DoD’s payment-due dates to decide which TRRx usage may be ascribed to the relevant reporting periods (See chart below). Covered drug scripts filled for TRICARE beneficiaries through the TRRx/T-Pharm Network should be treated by manufacturers as sales to the Federal Government, for non-FAMP reporting purpose, beginning on the payment-due date transmitted by DoD to the manufacturer in the File containing the manufacturer’s quarterly DoD usage data and refund invoice.

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Billing Period</th>
<th>Refund Payment Due Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q2 2020</td>
<td>April - June 2020</td>
<td>November 20, 2020</td>
</tr>
<tr>
<td>Q3 2020</td>
<td>July - September 2020</td>
<td>February 19, 2021</td>
</tr>
<tr>
<td>Q4 2020</td>
<td>October - December 2020</td>
<td>May 20, 2021</td>
</tr>
<tr>
<td>Q1 2021</td>
<td>January - March 2021</td>
<td>August 20, 2021</td>
</tr>
</tbody>
</table>

After PBM receives a company’s non-FAMP data, PBM will calculate the [Change in non-FAMP], [Additional Discount], and [2022 Federal Ceiling Price] for each covered drug item subject to the 2021 annual reporting requirements for 2022 FCPs. PBM will send you an Excel workbook (.xls) via e-mail of your company’s calculated 2022 FCPs after the non-FAMP data has been calculated. If your company does not agree with any of VA’s calculations of the FCPs, you must formally notify VA within two workdays after VA sends the email. If you submit any corrected annual non-FAMP reports, they will be accepted on a provisional basis but will be subject to review by the Office of Inspector General (OIG).

The quarterly non-FAMP report for the third quarter of 2021 consists of the same data as the “new non-FAMP” (07/01/2021 to 09/30/2021) reported on the 2021 annual calculation form, which is due by November 15, 2021. Consequently, it will not be necessary to submit the non-FAMP third quarter 2021 report separately. However, companies that do not meet the November 15, 2021 annual reporting deadline will be subject to penalties for late data reporting as described in the MA, paragraph (IV) (B). Please note that 38 U.S.C. 8126 (e) (2) and Sect. 1927 (b) (3) of the Social Security Act (reflected in the MA) impose a civil money penalty on late reporting manufacturers in the amount of $10,000.00 for each day in which required information has not been provided. VA asks that you submit the required annual data as soon as possible after the CPI-U change is posted in October and you receive this e-mail.

Section 8126 (e) of the Law states that quarterly non-FAMP reports are due 30 days after the end of the quarter. These figures should be as accurate as possible, since they serve as an indicator of pricing trends and will be used during OIG reviews. Nevertheless, to assist companies in providing the most accurate quarterly non-FAMP calculations possible, PBM will not seek imposition of late penalties for unreported data until 45 days after the end of each quarter. The same 45-day forbearance applies to filing Temporary and Permanent New Drug non-FAMPs. Again, please note that each year the non-FAMP third quarter data is submitted as part of the Annual Report (which is due 45 days after the end of the third quarter).

If you have any questions about any of the above information, please call Cheryl Kohutynski or Dustin Ehster, at (708) 786-7985 or (708) 786-4387, respectively.

Sincerely,

Jennifer Martin, PharmD
Deputy Chief Consultant
Pharmacy Benefits Management Services
VACO Pharmacy Service
VII. ATTACHMENTS

A. METHODOLOGY CHANGE REQUEST

DUE DATE: 10/29/2021

Purpose: Allows the company to request review and approval from VA of a change in their methodology used to calculate non-FAMP data for the 2021 annual reporting year, and to request approval of restated 3Q2020 (non-FAMP OLD) recalculation under the new methodology (for purposes of an apples-to-apples additional discount calculation). The VA Office of Inspector General OIG will review these requests and make recommendation to the VA. This request can also be used to notify VA and PBM of pending and approved requests. At this point, and to reduce e-mail traffic, a corrected workbook with revised data values will not be re-issued. The corrected values will be used in calculations and will reflect in the final FCP report to the company.

NOTE: This format is to request non-FAMP methodology changes in advance of the due date (Oct 29, 2021). Instructions: Requesting Modifications to Existing Methodology Used to Calculate non-FAMP

1. Prepare a letter requesting approval for a change in calculation methodology.
2. Specify the reasons for the change in methodology and provide all supporting documentation.
3. In the workbook, identify the 3Q 2020 values impacted by the methodology change.
4. Send original workbook via e-mail to AMMHIN.PL102585@va.gov including option (a), (b) or (c)—(see example e-mail below):
   a. For new requests, keep line number 1 in the body of the e-mail and populate the dispute_nfamp_old with “Y” and provide the rev_nfamp_old values
   b. For pending requests, keep line number 2 in the body of the e-mail and populate the dispute_nfamp_old with “Y” and provide the rev_nfamp_old values
   c. If VA has already approved your company’s methodology change request but the values in the annual workbook do not reflect the change, please send an e-mail to AMMHIN.PL102585@va.gov; populate the dispute_nfamp_old field with “Y” and populate the restated 3Q 2020 values in “rev_nfamp_old” fields; include documented OIG review and recommended approval and update the subject line with the FSS contract number and “Methodology Change Approved”
5. For options 4(a) & (b) above, subject line should include the full FSS contract number + manufacturer’s name, and the words “METHODOLOGY CHANGE”
6. OIG will review the request and any associated documentation prior to submitting its recommendation to the VA, who has the final decision. The 2020 3QNFAMP Old must be restated with the new methodology to ensure an apples-to-apples comparison for the purposes of the additional discount. If OIG recommends accepting the proposed methodology, OIG will communicate its recommendation to AMMHIN.PL102585@va.gov. The VA will then notify the contractor of its decision.
7. Upon approval, PBM will use the updated methodology (revised 3Q OLD values) to calculate 2022 FCPs

Example:

*Send to:* AMMHIN.PL102585@va.gov
*Subject:* 70307D00600 Methodology Change + Manufacturer Name

---

ATTN: Office of Inspector General

Dear VA,

FSS contract [insert full FSS contract number]:

1. I am submitting a new request for a change in the methodology used to calculate NFAMP data for this year’s Public Law.
2. I have already submitted a request for a change in methodology to calculate NFAMP data for this year’s Public Law, and would like an updated status.

Attached are the supporting document(s) for the change in methodology including the original Excel workbook received populated with 3Q NFAMP OLD values impacted by this change.

Sincerely,

Pharmaceutical Vendor

---
B. WORKBOOK VERIFICATION DISPUTES  RETURN DATE:  10/29/2021

Purpose: For the manufacturer to notify the VA of any disputes concerning the accuracy of the annual workbook contents provided for verification. Disputes can be a September 30 FSS price, and/or a 3Q CY 2020 (non-FAMP OLD) dispute (unrelated to methodology change) and/or a potentially omitted covered item(s). NOTE: This specific format is used to identify disputes in advance of the due date (October 29, 2021). After October 29, disputes should be reported with the annual filing due no later than November 15, 2021.

Instructions: How to Submit FSS price disputes and/or 3Q CY 2020 (non-FAMP Old) disputes unrelated to methodology changes and/or a potentially omitted covered item(s). NOTE: Items introduced after 04/01/2021 may not be included in this year’s annual workbook for 2022 FCP calculations (exceptions are covered drug NDC changes of existing item(s) and divested/acquired items).

1. Upon receipt of your company’s Excel workbook, review the covered items where potential disputes exist. Multiple disputes may exist in the Excel workbook.

2. To dispute the FSS price and/or 3Q CY 2020 price: Mark column W (Dispute_fss) with a “Y” in the Excel workbook; to dispute the 3Q CY 2020, mark column X (Dispute_nfamp_old) with a “Y” in the Excel workbook. See example below.

3. For each column populated with a “Y”, input a revised value in the respective column:
   a. For disputed FSS prices, input the revised FSS price in column Y (without IFF/FET).
   b. For disputed 3Q 2020 VALUES, input the revised 3Q 2020 value in column Z.

4. The following apply to inputs made in Column Y (rev_fss_price):
   a. Ensure the FSS price does not include the 0.5% Industrial Funding Fee (IFF)
   b. Ensure the FSS price does not include the Federal Excise Tax (FET) for vaccines
   c. Attach copies of modifications or contract award documents to support manufacturer’s FSS price dispute

5. The following apply to inputs made in column Z (rev_nfamp_old):
   a. Provide document(s) to support the disputed 3Q 2020 value(s)

6. Subject heading should include the full contract number and the words “Dispute Notification”

---

Dear VA,

Company ABC has reviewed their workbook. The following potential disputes have been identified (list all applicable disputes):

- FSS price as of Sept 30
- 3Q 2020 (nfamp_old) Dispute
- Omitted Item

As instructed in the DML, the original workbook and supporting documents have been submitted for consideration.
B. WORKBOOK VERIFICATION DISPUTES (cont’d) RETURN DATE: 10/29/2021

7. To notify PBM of a potential omission: Identify potential covered item(s) omitted from workbook.

8. In the body of the e-mail, provide the data for the following fields (see example below):
   ▪ NDC_11, Date of Market Entry, Trade & Generic Name
   ▪ Proposed 09/30 FSS price (without IFF/FET)
   ▪ 2021 annual non-FAMP value (10/01/2020 to 9/30/2021)
   ▪ 3Q Calendar Year 2020 (non-FAMPOLD) value (07/01/2020 to 09/30/2020), if applicable
   ▪ 3Q Calendar Year 2021 (non-FAMPNEW) value (07/01/2021 to 09/30/2021), if applicable
   ▪ Indicate if omitted item is due to a change of NDC (Yes/No/)
     ▷ If “Y”, please update Date Market Entry column with the date of the New NDC

Dear PBM:

FSS contract number [insert full or pending contract number here] believes the item(s) listed below should have been included in this year’s workbook for the following reason(s):

<table>
<thead>
<tr>
<th>NDC11</th>
<th>Date of Market Entry</th>
<th>Trade Name</th>
<th>Generic Name</th>
<th>Annual non-FAMP value</th>
<th>3Q non-FAMP OLD value</th>
<th>3Q non-FAMP NEW value</th>
<th>42-2A NDC Change (Y/N/?)</th>
<th>Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>0001222233</td>
<td>3/18/2020</td>
<td>DRUG BRAND CREAM</td>
<td>GENERIC CREAM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1111222233</td>
<td>3/28/2020</td>
<td>DRUG BRAND BOTTLE</td>
<td>GENERIC BOTTLE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

9. Subject heading should include the full contract number and the words “Dispute Notification”

10. The original Excel workbook received should be returned via e-mail to AMMHIN.PL102585@va.gov.

11. Attach copies of modifications or contract award documents to support manufacturer’s FSS price dispute.

12. PBM, FSS and OIG will work to resolve issues. Similar to the 2020 reporting year and to reduce e-mail traffic, a corrected workbook will not be re-issued. Omitted item(s) will be included in the final FCP report to the company.

13. PBM will only process the data after all disputes have been resolved. All corrected information will be included in the final 2022 FCP calculation workbook.

14. Unresolved item(s) will be tagged for follow-up in the 1Q 2022 CY, on a case by case basis.
**COMPLIANCE REMINDERS**

**Rounding** - Annual non-FAMP data includes sales from 10/01/2020 to 09/30/2021 (“nfamp” column “R” in Excel workbook) and Q3 non-FAMP NEW data includes sales from 07/01/2021 to 09/30/2021 (“nfamp_new” column “S” in Excel workbook) and must contain data (i.e., NULL or BLANK is not valid).

**Calculation is rounded to two decimal places; rounding up if 3rd decimal is >=5.** If there are no reportable sales for the covered item(s), enter “0.00”; negative values should be reported as such.

**Rounding Examples:**
- value of 2.1462 rounds to 2.15
- value of 2.149 rounds to 2.14

**Discontinuations** - Covered drug items that are contained in the annual workbook received from PBM but have a pending FSS discontinuation modification should still have a 2021 annual non-FAMP report filed to calculate a 2022 FCP; there is no need for a price-changing FSS Request for Modification (RFM) for 2022, if the stock of the discontinued drug at wholesalers is exhausted by about Dec. 1, 2021. (In such a case, a proper deletion FSS RFM would be filed before Jan. 1, 2021.) However, if sales of wholesaler stock will continue into 2022, the company must follow all the usual steps to have statutory pricing in place for 2022.

**Flu Vaccines** - The VA has established specific guidelines for reporting the provisional and permanent FCP data for influenza vaccines that are excluded from the workbook. Companies are expected to comply with the reporting requirements of the October 19, 2001 DML for reporting provisional FCP data. For reporting permanent FCP data for influenza vaccines, companies are expected to comply with the reporting requirements outlined in the March 31, 2004 DML.

**Eligibility** - Annual non-FAMP data will not be required to be reported for a new covered drug that was introduced into the commercial market after April 1, 2021 and has not experienced at least one full calendar quarter of sales by September 30, 2021. In addition, the item will not appear in the annual workbook for FCP calculations. (NDC changes are the exception to this rule).

**Permanent FCP establishment** - All new covered drugs that reach Permanent FCP stage after September 30, 2021 (that is, any product with a date of market entry after April 1, 2021) must be reported under separate e-mail from the 2021 annual report. These permanent FCPs will remain in effect for the 2021 calendar year and through the 2022 calendar year until the next annual filing due in November of 2022.

**Dear Manufacturer Letters (DML)** - Library of all DMLs available at the following website:

**NDC Changes** - If a manufacturer of a covered drug changes their NDC, the new NDC number must be added to the contract at the time of launch at the same FCP and contract pricing as the original NDC. Further, both the old and new NDC must remain on contract until the old NDC is off the market and out of the supply chain. The non-FAMP sales data for both the “old” and “new” NDCs must be combined (or blended) when reporting. If new covered drug NDC(s) are not included in the initial workbook received from the Public Law Manager, or if there is a pending FSS NDC Change modification, please follow the directions under omitted items (page 11). The new NDC(s) will be included in the final 2022 FCP workbook.

**Excel workbook** – Several of the cells in PBM’s Excel workbooks are locked and read-only. A copy of an unlocked Excel workbook will be supplied to companies upon request if needed for data processing. However, the final Excel workbook submitted to the Public Law Manager by companies must be the original locked Excel workbook received from PBM.

**TRICARE (TRRx)** - VA has provided further guidance to manufacturers on how to treat sales which become the basis for TRICARE Retail Pharmacy Program (TRRx) rebates (page 8). Additional guidance can be found at: https://health.mil/About-MHS/Defense-Health-Agency/Operations/Pharmacy-Division/Information-for-Pharmaceutical-Manufacturers/Contact-the-TRICARE-Retail-Refund-Team.

**FSS Contract Number Changes** - FSS contracts are awarded with a five-year duration period. Your FSS contract may be awarded a new contract number during Public Law season after the locked spreadsheet has been submitted to your company. The newly awarded contract number will be used for the final 2022
FCP workbook.

D. 2022 FCP DISPUTE PROCESS

Instructions: How to Submit a Dispute of the 2022 calculated FCPs for annual reporting year 2021

Purpose: Company is to use this format to dispute or resubmit data for 2022 FCP calculations that are the result of database and/or scrivener errors. If a company wishes to dispute an FCP because it believes the non-FAMP data it provided was in error, it should submit a self-disclosure under Attachment E rather than an FCP Dispute e-mail. If a company wishes to dispute an FCP that was calculated correctly, but it believes is unreasonably low, it should follow the guidance in the February 24, 1993 DML to submit an FCP increase appeal to the VA FCP Nominal Increase Board, via e-mail to AMMHIN.PL102585@va.gov.

1. In the report, identify all covered items where the 2022 FCP is being disputed due to a database error.

2. In the body of the e-mail, provide the values for the following fields:
   - NDC_11 and TRADE_NAME
   - Calculated FCP and Revised FCP
   - Revised 2021 non-FAMP value (10/01/2020 to 09/30/2021)
   - Revised 3Q Calendar Year 2021 non-FAMP value (07/01/2021 to 09/30/2021)
   - Reason for dispute

3. Include all documentation that would support the dispute or resubmission, as necessary.

4. Subject heading should include the full contract number and title “Dispute FCP Report”

NOTE: Resubmissions are limited to disputes resulting from database errors only and reports should be submitted via e-mail to nonfamp@va.gov.

Example:

Subject: V977-XXX DISPUTE Calculated FCP

To whom it may concern:

FSS contract V977-XXX is disputing the 2022 calculated FCP data for the following NDCs:

<table>
<thead>
<tr>
<th>NDC_11</th>
<th>TRADE_NAME</th>
<th>Calculated FCP</th>
<th>Revised FCP</th>
<th>Revised Annual NFAMP</th>
<th>Revised 3Q New NFAMP</th>
<th>Reason for Dispute</th>
</tr>
</thead>
<tbody>
<tr>
<td>11111122233</td>
<td>DRUG BRAND CREAM</td>
<td>52.79</td>
<td>65.92</td>
<td>75</td>
<td>N/A</td>
<td>Data entry error for ANNUAL NFAMP</td>
</tr>
<tr>
<td>00111234567</td>
<td>DRUG BRAND BOTTLE</td>
<td>32.78</td>
<td>34.78</td>
<td>34.58</td>
<td>18.2</td>
<td>Data entry error for ANNUAL NFAMP</td>
</tr>
</tbody>
</table>

The attached document(s) support the disputed calculated FCPs.

Sincerely,
Pharmaceutical Vendor

Examples of database errors/reasons in which PBM can immediately address:
- Revised 3Q 2020 value(s) approved, but not used for the 2022 FCP calculations
- Revised 3Q 2020 value(s) restated due to an approved change in the non-FAMP calculation methodology
- Revised Sep 30 FSS price was approved, but not used for the 2022 FCP calculations
- Omitted item(s) had incorrect 3Q 2020 value applied for the 2022 FCP calculations

Scrivener’s errors during entry (e.g., 3Q values were entered into the annual fields)

NOTE: Due to the time constraints and review processes involved, 2022 calculated FCPs unrelated to database errors may be delayed.
E. SELF-DISCLOSURE

Instructions: How to Submit a Self-disclosure for Federal Supply Schedule (FSS) Public Law Non-Compliance or Pricing Errors

Purpose: Provides the manufacturer with a process for making a self-disclosure of any Public Law non-compliance or pricing errors that occurred during any period the manufacturer was subject to the Public Law (manufacturing and selling covered drug products). The AMMHN.PL102585@va.gov mailbox will rout self-disclosures to the OIG and the VA Office of General Counsel (OGC) for initial review.

Examples of non-compliance or pricing errors requiring disclosure include (but are not limited to):

- Failure to obtain an FSS contract and sign a Master Agreement in a timely manner
- Failure to submit non-FAMP data and add a new covered drug to an FSS contract in a timely manner
- Errors in calculating non-FAMPs
- Misclassifying covered drugs as non-covered drugs
- Deleting covered drugs from an FSS contract prematurely
- Price Reductions Clause Violations that impacted the FCPs
- Incorrect treatment of:
  - NDC number changes
  - New Package Sizes
  - Transferred Drugs

To make a self-disclosure, a manufacturer should do the following:

Prepare a letter that states the non-compliance error, what caused the error, what covered drug item(s) (including NDC #s) were affected by the error, specific date ranges when the error(s) occurred, and what remedial action the manufacturer is proposing or has taken.

1. Provide the first commercial sale dates of all NDCs involved, for all self-disclosure issues.
2. Estimated overcharges owed to the Government, if known. If not known, please state this fact in the disclosure letter and explain why an estimated overcharges amount cannot be provided.
3. For transferred drug treatment errors, provide the date that the transferee obtained full legal rights and responsibilities for the products, the transferee’s first commercial sale dates, explanation of the treatment of the transferor’s remaining inventory, and details of any interim arrangements between the transferor and transferee regarding sales of the products and sales reporting responsibilities to the VA for IFF purposes.
4. For new package size errors, please provide the NDC number used as the closest package size and the pro-rated calculations.
5. Provide supporting documentation for the disclosure including the original and restated non-FAMPS and related FCPs and the detailed non-FAMP methodology used in the calculations.
6. Provide the point of contact(s) for OIG to contact if a review is needed.
7. Send the disclosure letter via e-mail notification to AMMHN.PL102585@va.gov.
8. The email Subject should include the full FSS contract number, manufacturer’s name, and the words: “Self- Disclosure”.

14
Example:

Subject: V797P-XXXXX Manufacturer Name - Self-disclosure
Attached: Provide all supporting documents

Dear OGC/OIG:

FSS contract V797P-XXXXX would like to report that during a self audit we have discovered the following issues over the course of X years.

Describe the issue

Provide all supporting documentation and contact phone numbers.

Sincerely,

Pharmaceutical Vendor
F. APPEAL TO THE NOMINAL INCREASE BOARD

Instructions: How to Submit a request to the Nominal Increase Board for FCP increases

Purpose: Provides the manufacturer with a process for making an appeal to the Nominal Increase Board to increase the FCP if it is determined that selling at that price would cause the manufacturer to lose money in its overall business. The AMMHIN.PL102585@va.gov mailbox will route appeal to the OIG who will review the appeal and make its recommendation to the Nominal Increase Board.


Before submitting an appeal to the Nominal Increase Board, the manufacturer should first consider if a change in non-FAMP methodology (for example, smoothing the 3Q NFAMPs) eliminates the financial problem.

To submit an appeal letter to the Nominal Increase Board, all of the following information must be sent to the AMMHIN.PL102585@va.gov mailbox:

1. The formal nominal increase materials that are outlined in the 1993 Dear Manufacturer Letter (DML). This includes:
   a. The certification signed by the president of the company found on page 3 of the DML.
   b. Justification for the increase for each NDC item
   c. Financial problem that allegedly exists with the statutorily calculated FCP
   d. Explanation of how it would be in the best interests of VA or another Federal agency to pay more for a covered drug product than the statutory formula specifies
2. The total overall volume of commercial sales for all products marketed.
3. The sales percentage of the NDCs that relief is being requested to overall sales of all products marketed.
4. The sales percentage of total Government sales to total sales volume.
5. The Cost of Goods Sold per unit for each NDC in the format shown below:
   a. Direct Materials
   b. Direct Labor
   c. Fixed Overhead (specific overhead costs must be defined and itemized)
   d. Variable Overhead (specific overhead costs must be defined and itemized)
   e. Other Costs (each type of other cost must be defined and itemized)

<table>
<thead>
<tr>
<th>NDC #</th>
<th>Product Name</th>
<th>NDC #</th>
<th>Product Name</th>
<th>NDC #</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2022 FCP Currently in Place</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less: Cost of Goods Sold - Per Unit</td>
</tr>
<tr>
<td>Direct Materials</td>
</tr>
<tr>
<td>Direct Labor</td>
</tr>
<tr>
<td>Fixed Overhead</td>
</tr>
<tr>
<td>Variable Overhead</td>
</tr>
</tbody>
</table>

Total Cost of Goods Sold $0.00 $0.00 $0.00

Other Costs -- Please Detail and Define

Total Other Costs $0.00 $0.00 $0.00

Net Profit/Loss Per Unit $0.00 $0.00 $0.00

6. Provide the point of contact(s) for OIG for follow-up questions.
7. Email the appeal letter to the AMMHIN.PL102585@va.gov mailbox
8. The email Subject should include the full FSS contract number, manufacturer’s name, and the words: “Appeal to the Nominal Increase Board”.

16